BioCryst Pharmaceuticals, Inc. (BCRX) SEC Filings & Earnings Calls

Dependence on ORLADEYO for majority of revenue; pipeline assets still in clinical stages.

“ORLADEYO revenue $158.2M vs total $218.3M; navenibart and BCX17725 not yet approved.”

R&D expenses increased due to navenibart study; future costs uncertain.

“R&D expenses $46.5M (+37% yoy) primarily due to ALPHA-ORBIT study.”

Integration Risk from Astria Acquisition

“The anticipated benefits and synergies of the Merger may not be realized, and risks associated with Astria's business or product candidates could adversely affect our business.” · word for word

High Leverage from New Term Loan

“Secured term loan $395,400k at June 30, 2026 (from $0 at Dec 2025).”

Product Sales Decline

“Product sales, net $157,513 (Q2 2026) vs $162,430 (Q2 2025), a 3% decline.”

Restructuring execution risk: costs not yet estimable; potential for higher-than-expected charges.

“Company currently unable to estimate total amount or range of costs.”

Operational disruption: closure of Birmingham facility may impact ongoing research activities.

“Closure of Discovery Center of Excellence facility.”

Potential dilution from increased share reserve under stock incentive plan.

“7,000,000 additional shares authorized for issuance.”

Acquisition integration risk

“Acquired in-process research and development $697,761 for three months ended March 31, 2026.”

Debt service risk

“Secured term loan $395,197 at March 31, 2026.”

Regulatory and commercial execution risk for navenibart in Europe.

“Navenibart is an investigational product; Phase 3 program ongoing.”

Underwater stock options reduce incentive value

“approximately 26% of the shares underlying all outstanding stock option awards under the Stock Incentive Plan are underwater (with an exercise price in excess of the closing price of our Common Stock on April 13, 2026).”

Elevated equity overhang

“the approximately 54,027,003 shares reserved or currently available for issuance under the Stock Incentive Plan (without taking into account the Share Increase) represent an overhang of approximately 18%” · word for word

Dependence on ORLADEYO for revenue; pipeline products still in clinical development.

“Revenue primarily from ORLADEYO; navenibart Phase 3 program not expected to support regulatory filing until end of 2027.”

Dependence on ORLADEYO

“ORLADEYO is our only approved product and accounts for substantially all of our revenue.”

Clinical trial risk for pipeline assets

“Our success depends in part upon our ability to manage our product candidate pipeline, advance our product candidates through the various stages of development, especially through the clinical trial process.” · word for word

Debt and royalty obligations

“The Blackstone Loan Agreement (as defined below) contains conditions and restrictions that limit our flexibility in operating our business.” · word for word

Integration risk and potential dilution from stock consideration; Astria was pre-revenue with significant R&D expenses.

“Astria had net loss of $31.6M in Q3 2025 and accumulated deficit of $773.2M. BioCryst issued 0.59 shares per Astria share, causing dilution.”

Dependence on single product ORLADEYO; European revenue sale reduces geographic diversification.

“ORLADEYO is primary revenue driver; European business sold.”

Integration risk from proposed Astria acquisition.

“Proposed acquisition of Astria Therapeutics expected to close in Q1 2026.”

Drug pricing pressure may intensify if payers push back on the increase.

“WAC increase of ~9% could attract scrutiny from payers or regulators.”

Merger completion risk

“We face risks relating to the proposed Merger and our ability to consummate the Merger, including that failure to complete the Merger could negatively impact us, the pending Merger may disrupt our ongoing business operations, and we may fail to realize the anticipated benefits of the Merger.” · word for word

Indebtedness and covenant risk

“We anticipate incurring significant indebtedness in connection with the Commitment Letter (as defined below), and the definitive documentation for such indebtedness may contain conditions and restrictions that limit our flexibility in operating our business.” · word for word

Competitive pressure from new prophylactic HAE therapies; new patient adds only slightly beat Q3 2024 despite market entry of competitors.

“New patient prescriptions in the third quarter were strong, slightly beating those in Q3 2024 despite the recent launches of new prophylactic competitors.” · word for word

Acquisition integration risk for Astria Therapeutics; transaction expected to close Q1 2026.

“Definitive agreement signed to acquire Astria Therapeutics; transaction expected to close Q1 2026” · word for word

CEO transition; Jon Stonehouse stepping down after 19 years; new CCO appointed.

“It has been an incredible honor to lead the employees of BioCryst over these past nearly 19 years.” · word for word